Small cell lung cancer transformation and T790M mutation

Complimentary roles in acquired resistance to kinase inhibitors in lung cancer

Kenichi Suda, Isao Murakami, Kazuko Sakai, Hiroshi Mizuuchi, Shigeki Shimizu, Katsuaki Sato, Kenji Tomizawa, Shuta Tomida, Yasushi Yatabe, Kazuto Nishio, Tetsuya Mitsudomi

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Lung cancers often harbour a mutation in the epidermal growth factor receptor (EGFR) gene. Because proliferation and survival of lung cancers with EGFR mutation solely depend on aberrant signalling from the mutated EGFR, these tumours often show dramatic responses to EGFR tyrosine kinase inhibitors (TKIs). However, acquiring resistance to these drugs is almost inevitable, thus a better understanding of the underlying resistance mechanisms is critical. Small cell lung cancer (SCLC) transformation is a relatively rare acquired resistance mechanism that has lately attracted considerable attention. In the present study, through an in-depth analysis of multiple EGFR-TKI refractory lesions obtained from an autopsy case, we observed a complementary relationship between SCLC transformation and EGFR T790M secondary mutation (resistance mutation). We also identified analogies and differences in genetic aberration between a TKI-refractory lesion with SCLC transformation and one with EGFR T790M mutation. In particular, target sequencing revealed a TP53 P151S mutation in all pre- and post-Treatment lesions. PTEN M264I mutation was identified only in a TKI-refractory lesion with SCLC transformation, while PIK3CA and RB1 mutations were identified only in pre-Treatment primary tumour samples. These results provide the groundwork for understanding acquired resistance to EGFR-TKIs via SCLC transformation.

Original languageEnglish
Article number14447
JournalScientific Reports
Volume5
DOIs
Publication statusPublished - Sep 24 2015
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Lung Neoplasms
Phosphotransferases
Mutation
Protein-Tyrosine Kinases
erbB-1 Genes
Drug Resistance
Autopsy
Neoplasms

ASJC Scopus subject areas

  • General

Cite this

Small cell lung cancer transformation and T790M mutation : Complimentary roles in acquired resistance to kinase inhibitors in lung cancer. / Suda, Kenichi; Murakami, Isao; Sakai, Kazuko; Mizuuchi, Hiroshi; Shimizu, Shigeki; Sato, Katsuaki; Tomizawa, Kenji; Tomida, Shuta; Yatabe, Yasushi; Nishio, Kazuto; Mitsudomi, Tetsuya.

In: Scientific Reports, Vol. 5, 14447, 24.09.2015.

Research output: Contribution to journalArticle

Suda, K, Murakami, I, Sakai, K, Mizuuchi, H, Shimizu, S, Sato, K, Tomizawa, K, Tomida, S, Yatabe, Y, Nishio, K & Mitsudomi, T 2015, 'Small cell lung cancer transformation and T790M mutation: Complimentary roles in acquired resistance to kinase inhibitors in lung cancer', Scientific Reports, vol. 5, 14447. https://doi.org/10.1038/srep14447
Suda, Kenichi ; Murakami, Isao ; Sakai, Kazuko ; Mizuuchi, Hiroshi ; Shimizu, Shigeki ; Sato, Katsuaki ; Tomizawa, Kenji ; Tomida, Shuta ; Yatabe, Yasushi ; Nishio, Kazuto ; Mitsudomi, Tetsuya. / Small cell lung cancer transformation and T790M mutation : Complimentary roles in acquired resistance to kinase inhibitors in lung cancer. In: Scientific Reports. 2015 ; Vol. 5.
@article{7d90de5ca2fe4dbebbbacd1203968d49,
title = "Small cell lung cancer transformation and T790M mutation: Complimentary roles in acquired resistance to kinase inhibitors in lung cancer",
abstract = "Lung cancers often harbour a mutation in the epidermal growth factor receptor (EGFR) gene. Because proliferation and survival of lung cancers with EGFR mutation solely depend on aberrant signalling from the mutated EGFR, these tumours often show dramatic responses to EGFR tyrosine kinase inhibitors (TKIs). However, acquiring resistance to these drugs is almost inevitable, thus a better understanding of the underlying resistance mechanisms is critical. Small cell lung cancer (SCLC) transformation is a relatively rare acquired resistance mechanism that has lately attracted considerable attention. In the present study, through an in-depth analysis of multiple EGFR-TKI refractory lesions obtained from an autopsy case, we observed a complementary relationship between SCLC transformation and EGFR T790M secondary mutation (resistance mutation). We also identified analogies and differences in genetic aberration between a TKI-refractory lesion with SCLC transformation and one with EGFR T790M mutation. In particular, target sequencing revealed a TP53 P151S mutation in all pre- and post-Treatment lesions. PTEN M264I mutation was identified only in a TKI-refractory lesion with SCLC transformation, while PIK3CA and RB1 mutations were identified only in pre-Treatment primary tumour samples. These results provide the groundwork for understanding acquired resistance to EGFR-TKIs via SCLC transformation.",
author = "Kenichi Suda and Isao Murakami and Kazuko Sakai and Hiroshi Mizuuchi and Shigeki Shimizu and Katsuaki Sato and Kenji Tomizawa and Shuta Tomida and Yasushi Yatabe and Kazuto Nishio and Tetsuya Mitsudomi",
year = "2015",
month = "9",
day = "24",
doi = "10.1038/srep14447",
language = "English",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Small cell lung cancer transformation and T790M mutation

T2 - Complimentary roles in acquired resistance to kinase inhibitors in lung cancer

AU - Suda, Kenichi

AU - Murakami, Isao

AU - Sakai, Kazuko

AU - Mizuuchi, Hiroshi

AU - Shimizu, Shigeki

AU - Sato, Katsuaki

AU - Tomizawa, Kenji

AU - Tomida, Shuta

AU - Yatabe, Yasushi

AU - Nishio, Kazuto

AU - Mitsudomi, Tetsuya

PY - 2015/9/24

Y1 - 2015/9/24

N2 - Lung cancers often harbour a mutation in the epidermal growth factor receptor (EGFR) gene. Because proliferation and survival of lung cancers with EGFR mutation solely depend on aberrant signalling from the mutated EGFR, these tumours often show dramatic responses to EGFR tyrosine kinase inhibitors (TKIs). However, acquiring resistance to these drugs is almost inevitable, thus a better understanding of the underlying resistance mechanisms is critical. Small cell lung cancer (SCLC) transformation is a relatively rare acquired resistance mechanism that has lately attracted considerable attention. In the present study, through an in-depth analysis of multiple EGFR-TKI refractory lesions obtained from an autopsy case, we observed a complementary relationship between SCLC transformation and EGFR T790M secondary mutation (resistance mutation). We also identified analogies and differences in genetic aberration between a TKI-refractory lesion with SCLC transformation and one with EGFR T790M mutation. In particular, target sequencing revealed a TP53 P151S mutation in all pre- and post-Treatment lesions. PTEN M264I mutation was identified only in a TKI-refractory lesion with SCLC transformation, while PIK3CA and RB1 mutations were identified only in pre-Treatment primary tumour samples. These results provide the groundwork for understanding acquired resistance to EGFR-TKIs via SCLC transformation.

AB - Lung cancers often harbour a mutation in the epidermal growth factor receptor (EGFR) gene. Because proliferation and survival of lung cancers with EGFR mutation solely depend on aberrant signalling from the mutated EGFR, these tumours often show dramatic responses to EGFR tyrosine kinase inhibitors (TKIs). However, acquiring resistance to these drugs is almost inevitable, thus a better understanding of the underlying resistance mechanisms is critical. Small cell lung cancer (SCLC) transformation is a relatively rare acquired resistance mechanism that has lately attracted considerable attention. In the present study, through an in-depth analysis of multiple EGFR-TKI refractory lesions obtained from an autopsy case, we observed a complementary relationship between SCLC transformation and EGFR T790M secondary mutation (resistance mutation). We also identified analogies and differences in genetic aberration between a TKI-refractory lesion with SCLC transformation and one with EGFR T790M mutation. In particular, target sequencing revealed a TP53 P151S mutation in all pre- and post-Treatment lesions. PTEN M264I mutation was identified only in a TKI-refractory lesion with SCLC transformation, while PIK3CA and RB1 mutations were identified only in pre-Treatment primary tumour samples. These results provide the groundwork for understanding acquired resistance to EGFR-TKIs via SCLC transformation.

UR - http://www.scopus.com/inward/record.url?scp=84942155005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942155005&partnerID=8YFLogxK

U2 - 10.1038/srep14447

DO - 10.1038/srep14447

M3 - Article

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 14447

ER -